Dymedso is incorporated by Louis Plante and Yvon Robert
With the support of the Canadian Cystic Fibrosis Foundation, the Centre Hospitalier Universitaire de Sherbrooke and the Centre Hospitalier de l’Université de Montréal conduct a clinical study to demonstrate the safety and effectiveness of the Frequencer® to help clear secretions from the airways of individuals with Cystic Fibrosis.
Read the Frequencer® Clinical Study
Dymedso launches its first digitally-controlled acoustic airway clearance device and obtains Health Canada license.
A Proof of Concept by Maisonneuve-Rosemont Hospital in Montreal, QC, Canada, shows the efficiency of the Frequencer® compared to conventional airway drainage methods (Acapella, Flutter, Percussor, and Clapping).
Frequencer® is approved by the US Food & Drug Administration.
University of California San Diego Medical Center demonstrates the Frequencer® could safely be considered a preferred method by both patients and respiratory care practitioners for sputum production when treating Cystic Fibrosis.
NICU of renowned California hospital purchases Frequencer® for use with neonatal patients.
Dymedso obtains the CE mark demonstrating the Frequencer® meets the EU standards for health, safety and environmental protection.
Louis Plante is internationally honored with Patient Innovation Award
A study by the California Pacific Medical Center uses the Frequencer® for treatment of atelectasis, pneumonia, CF, RSV bronchiolitis and neuromuscular disease in pediatric patients to demonstrate shortened length of stay in the hospital.
Dymedso becomes a woman-led firm with Kim Anderson becoming the President.
Dymedso distributes 24 Frequencer® devices to twelve Québec healthcare institutions to treat COVID-19.
Dymedso distributes 29 devices to Toronto Grace Hospital for COVID-19 treatment and post-COVID rehab
National Korányi Institute shows effectiveness of Frequencer® vs HFCWO